Amicus Therapeutics, Inc. (0HF9.L)
USD 6.57
(-2.94%)
USD 6.57
(-2.94%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -151.58 Million USD | 35.92% |
| 2022 | -236.56 Million USD | 5.55% |
| 2021 | -250.46 Million USD | 9.53% |
| 2020 | -276.85 Million USD | 22.32% |
| 2019 | -356.38 Million USD | -2.12% |
| 2018 | -348.99 Million USD | -22.88% |
| 2017 | -284 Million USD | -41.97% |
| 2016 | -200.04 Million USD | -51.41% |
| 2015 | -132.11 Million USD | -91.68% |
| 2014 | -68.92 Million USD | -15.58% |
| 2013 | -59.63 Million USD | -22.24% |
| 2012 | -48.78 Million USD | -9.85% |
| 2011 | -44.41 Million USD | 19.16% |
| 2010 | -54.93 Million USD | -736.55% |
| 2009 | -6.56 Million USD | 83.31% |
| 2008 | -39.35 Million USD | 4.4% |
| 2007 | -41.16 Million USD | 11.17% |
| 2006 | -46.34 Million USD | -132.05% |
| 2005 | -19.97 Million USD | -126.77% |
| 2004 | -8.8 Million USD | -30.13% |
| 2003 | -6.76 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -15.69 Million USD | 67.58% |
| 2024 Q1 | -48.41 Million USD | -43.07% |
| 2023 Q4 | -33.84 Million USD | -56.85% |
| 2023 Q1 | -52.93 Million USD | 5.25% |
| 2023 FY | -151.58 Million USD | 35.92% |
| 2023 Q2 | -43.23 Million USD | 18.33% |
| 2023 Q3 | -21.57 Million USD | 50.09% |
| 2022 Q4 | -55.86 Million USD | -67.83% |
| 2022 FY | -236.56 Million USD | 5.55% |
| 2022 Q1 | -85.26 Million USD | -2.38% |
| 2022 Q2 | -62.15 Million USD | 27.1% |
| 2022 Q3 | -33.28 Million USD | 46.45% |
| 2021 Q2 | -51.22 Million USD | 21.99% |
| 2021 Q4 | -83.27 Million USD | -65.58% |
| 2021 FY | -250.46 Million USD | 9.53% |
| 2021 Q1 | -65.66 Million USD | 8.03% |
| 2021 Q3 | -50.29 Million USD | 1.82% |
| 2020 Q3 | -64.01 Million USD | -21.94% |
| 2020 Q1 | -88.94 Million USD | 0.87% |
| 2020 Q2 | -52.49 Million USD | 40.99% |
| 2020 FY | -276.85 Million USD | 22.32% |
| 2020 Q4 | -71.4 Million USD | -11.54% |
| 2019 Q2 | -84.55 Million USD | 29.72% |
| 2019 Q4 | -89.72 Million USD | -45.17% |
| 2019 Q3 | -61.8 Million USD | 26.9% |
| 2019 Q1 | -120.29 Million USD | -54.07% |
| 2019 FY | -356.38 Million USD | -2.12% |
| 2018 Q2 | -61.83 Million USD | -23.87% |
| 2018 Q4 | -78.08 Million USD | 50.94% |
| 2018 FY | -348.99 Million USD | -22.88% |
| 2018 Q1 | -49.91 Million USD | 27.88% |
| 2018 Q3 | -159.16 Million USD | -157.41% |
| 2017 Q1 | -54.99 Million USD | 6.23% |
| 2017 FY | -284 Million USD | -41.97% |
| 2017 Q4 | -69.2 Million USD | 38.02% |
| 2017 Q3 | -111.66 Million USD | -131.98% |
| 2017 Q2 | -48.13 Million USD | 12.47% |
| 2016 Q2 | -51.05 Million USD | -16.84% |
| 2016 FY | -200.04 Million USD | -51.41% |
| 2016 Q4 | -58.64 Million USD | -25.71% |
| 2016 Q3 | -46.65 Million USD | 8.61% |
| 2016 Q1 | -43.69 Million USD | -1.85% |
| 2015 FY | -132.11 Million USD | -91.68% |
| 2015 Q4 | -42.89 Million USD | -13.48% |
| 2015 Q3 | -37.8 Million USD | -39.31% |
| 2015 Q2 | -27.13 Million USD | -11.71% |
| 2015 Q1 | -24.28 Million USD | -14.46% |
| 2014 Q2 | -14.61 Million USD | 8.34% |
| 2014 Q3 | -17.14 Million USD | -17.35% |
| 2014 Q1 | -15.94 Million USD | -30.29% |
| 2014 FY | -68.92 Million USD | -15.58% |
| 2014 Q4 | -21.21 Million USD | -23.73% |
| 2013 Q2 | -15.34 Million USD | 12.08% |
| 2013 Q4 | -12.23 Million USD | 16.12% |
| 2013 Q1 | -17.45 Million USD | -74.32% |
| 2013 Q3 | -14.58 Million USD | 4.95% |
| 2013 FY | -59.63 Million USD | -22.24% |
| 2012 Q2 | -9.34 Million USD | 28.88% |
| 2012 Q4 | -10.01 Million USD | 38.52% |
| 2012 Q3 | -16.29 Million USD | -74.36% |
| 2012 Q1 | -13.13 Million USD | -51.66% |
| 2012 FY | -48.78 Million USD | -9.85% |
| 2011 Q4 | -8.66 Million USD | 11.24% |
| 2011 Q3 | -9.75 Million USD | 22.8% |
| 2011 Q1 | -13.35 Million USD | 11.52% |
| 2011 Q2 | -12.64 Million USD | 5.31% |
| 2011 FY | -44.41 Million USD | 19.16% |
| 2010 Q4 | -15.08 Million USD | 1.75% |
| 2010 FY | -54.93 Million USD | -736.55% |
| 2010 Q3 | -15.35 Million USD | -35.72% |
| 2010 Q2 | -11.31 Million USD | 14.12% |
| 2010 Q1 | -13.17 Million USD | -139.98% |
| 2009 FY | -6.56 Million USD | 83.31% |
| 2009 Q4 | 32.95 Million USD | 345.41% |
| 2009 Q3 | -13.42 Million USD | 1.42% |
| 2009 Q2 | -13.62 Million USD | -9.23% |
| 2009 Q1 | -12.47 Million USD | 11.86% |
| 2008 Q1 | -7.73 Million USD | 34.33% |
| 2008 FY | -39.35 Million USD | 4.4% |
| 2008 Q3 | -8.18 Million USD | 11.99% |
| 2008 Q2 | -9.29 Million USD | -20.22% |
| 2008 Q4 | -14.15 Million USD | -72.98% |
| 2007 Q3 | -10.3 Million USD | -9.65% |
| 2007 Q1 | -9.69 Million USD | 16.32% |
| 2007 Q4 | -11.77 Million USD | -14.27% |
| 2007 FY | -41.16 Million USD | 11.17% |
| 2007 Q2 | -9.39 Million USD | 3.08% |
| 2006 FY | -46.34 Million USD | -132.05% |
| 2006 Q2 | -11.58 Million USD | 0.0% |
| 2006 Q1 | -11.58 Million USD | -132.05% |
| 2006 Q4 | -11.58 Million USD | 0.0% |
| 2006 Q3 | -11.58 Million USD | 0.0% |
| 2005 Q1 | -4.99 Million USD | 0.0% |
| 2005 Q3 | -4.99 Million USD | 0.0% |
| 2005 Q2 | -4.99 Million USD | 0.0% |
| 2005 Q4 | -4.99 Million USD | 0.0% |
| 2005 FY | -19.97 Million USD | -126.77% |
| 2004 FY | -8.8 Million USD | -30.13% |
| 2003 FY | -6.76 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 50.861% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -179.737% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -71.318% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 56.947% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 45.103% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -27.905% |
| Imunon, Inc. | -19.51 Million USD | -676.757% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2272.578% |
| Editas Medicine, Inc. | -153.21 Million USD | 1.067% |
| FibroGen, Inc. | -284.23 Million USD | 46.669% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 65.862% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -259.212% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 160.706% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 71.718% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 11618.541% |
| Verastem, Inc. | -87.36 Million USD | -73.503% |
| Zoetis Inc. | 2.34 Billion USD | 106.467% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 104.188% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 41.208% |
| Homology Medicines, Inc. | -53.74 Million USD | -182.053% |
| Nektar Therapeutics | -276.05 Million USD | 45.089% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -76.476% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -280.291% |
| Perrigo Company plc | -12.7 Million USD | -1093.575% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 27.558% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.245% |
| Illumina, Inc. | -1.16 Billion USD | 86.944% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 102.529% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 111.162% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -37.107% |
| Waters Corporation | 642.23 Million USD | 123.603% |
| Biogen Inc. | 1.16 Billion USD | 113.055% |
| Evolus, Inc. | -61.68 Million USD | -145.739% |
| Adicet Bio, Inc. | -142.65 Million USD | -6.257% |
| bluebird bio, Inc. | -211.91 Million USD | 28.469% |
| Geron Corporation | -184.12 Million USD | 17.674% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 65.568% |
| Myriad Genetics, Inc. | -112 Million USD | -35.343% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 68.498% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 119.218% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -239.849% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 190.42% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 103.834% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 112.225% |
| OPKO Health, Inc. | -188.86 Million USD | 19.739% |
| Exelixis, Inc. | 207.76 Million USD | 172.959% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 242.815% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -219.091% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 36.639% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 58.616% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 153.831% |
| Blueprint Medicines Corporation | -506.98 Million USD | 70.101% |
| Insmed Incorporated | -749.56 Million USD | 79.777% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1296.212% |
| Incyte Corporation | 597.59 Million USD | 125.366% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 80.068% |